Literature DB >> 2544684

Hypertension in long-term survivors of childhood renal cancers.

A F Kantor1, F P Li, A J Janov, N J Tarbell, S E Sallan.   

Abstract

The prevalence of hypertension was investigated in 119 adults who have survived for up to 53 years following the diagnosis of renal cancer in childhood (Wilms' tumor, 116 patients; renal carcinoma, three patients). Twenty-four (20%) have developed definite or borderline hypertension, as compared with 18.1 cases expected based on US population rates (relative risk [RR], 1.3; 95% confidence interval [CI], 0.9 to 2.0; P = .20). This nonsignificant excess is due to the heightened prevalence of definite hypertension among one subgroup of male patients. The findings are not explained by cigarette smoking, obesity, age, and stage at diagnosis of Wilms' tumor, or family history of hypertension. A case-comparison analysis within the cohort showed no consistent hypertensive effect associated with radiation therapy dose, radiotherapy concurrent with dactinomycin chemotherapy, or extent of renal surgery. Hypertension is not a common late complication of Wilms' tumor in our patients.

Entities:  

Mesh:

Year:  1989        PMID: 2544684     DOI: 10.1200/JCO.1989.7.7.912

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

1.  Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study.

Authors:  Amanda M Termuhlen; Jean M Tersak; Qi Liu; Yutaka Yasui; Marilyn Stovall; Rita Weathers; Melvin Deutsch; Charles A Sklar; Kevin C Oeffinger; Greg Armstrong; Leslie L Robison; Daniel M Green
Journal:  Pediatr Blood Cancer       Date:  2011-03-07       Impact factor: 3.167

2.  Blood Pressure Status in Adult Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study.

Authors:  Todd M Gibson; Zhenghong Li; Daniel M Green; Gregory T Armstrong; Daniel A Mulrooney; DeoKumar Srivastava; Nickhill Bhakta; Kirsten K Ness; Melissa M Hudson; Leslie L Robison
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-22       Impact factor: 4.254

Review 3.  Damage to the urinary tract secondary to irradiation.

Authors:  J Fichtner; R Hohenfellner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

4.  Premature Atherosclerotic Cardiovascular Disease in Childhood Cancer Survivors.

Authors:  Charles W Shepard; Julia Steinberger
Journal:  Prog Pediatr Cardiol       Date:  2015-11-17

5.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

6.  Nephrotoxicity in survivors of Wilms' tumours in the North of England.

Authors:  S Bailey; A Roberts; C Brock; L Price; A W Craft; R Kilkarni; R E J Lee; A W Skillen; R Skinner
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

7.  Inhibition of DNA-PKcs enhances radiosensitivity and increases the levels of ATM and ATR in NSCLC cells exposed to carbon ion irradiation.

Authors:  Lina Yang; Yuanyuan Liu; Chao Sun; Xinrui Yang; Zhen Yang; Juntao Ran; Qiuning Zhang; Hong Zhang; Xinyu Wang; Xiaohu Wang
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

8.  DNA-PKcs inhibition sensitizes cancer cells to carbon-ion irradiation via telomere capping disruption.

Authors:  Xin Zhou; Xin Zhang; Yi Xie; Kaoru Tanaka; Bing Wang; Hong Zhang
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

9.  Renal size and function after cure of Wilms' tumour.

Authors:  G A Levitt; E Yeomans; C Dicks Mireaux; F Breatnach; J Kingston; J Pritchard
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

10.  Tumor Cell-Accelerated Senescence Is Associated With DNA-PKcs Status and Telomere Dysfunction Induced by Radiation.

Authors:  Miaomiao Zhang; Xiaopeng Guo; Yue Gao; Dong Lu; Wenjian Li
Journal:  Dose Response       Date:  2018-04-23       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.